BaroFeronTM
BaroFeron is a proprietary recombinant human interferon beta being developed for the treatment of Multiple Sclerosis. Interferon beta products are considered the ‘gold’ standard for first line treatment options for managing the progression of Multiple Sclerosis. However, clinical evidence and physician surveys indicate the need to improve upon the efficacy and safety of currently available therapies. BaroFeron will be differentiated from other interferon-beta products by improved safety and greater bioavailability enabled by BaroFold's proprietary PreEMTTM technology. BaroFold is aggressively implementing our clinical and regulatory strategy in preparation for a rapid launch.
Download the BaroFeron poster presented at the CMSC meeting in May, 2008
Download the BaroFeron poster presented at the AAN meeting in April, 2008
